Sesame lignans reduce LDL oxidative susceptibility by downregulating the platelet-activating factor acetylhydrolase
Y. Nakamura, H. Okumura, Y. Ono, Y. Kitagawa, T. Rogi, H. Shibata Institute for Health Care Science, Suntory Wellness Limited, Kyoto, Japan. Yoshiko_Toyoda@suntory.co.jp
OBJECTIVE: Low-density lipoprotein (LDL) oxidative susceptibility is recognized as a risk factor for atherosclerosis. We previously reported that the ingestion of a supplement containing sesame lignans (sesamin/episesamin) for 4 weeks reduced LDL oxidative susceptibility in humans.
MATERIALS AND METHODS: To elucidate the mechanisms underlying this observation, 12-week-old New Zealand White rabbits were fed a fat/cholesterol-enriched diet (100 g/day) for 6 weeks followed by oral administration of vehicle (control) or sesame lignans (50 mg/kg) for 4 weeks with the fat/cholesterol-enriched diet.
RESULTS: The results showed that the ingestion of sesame lignans prolonged LDL oxidation lag time, regardless of the existence of the anti-oxidative catechol metabolite of sesamin/episesamin in LDL. Plasma platelet-activating factor acetylhydrolase (PAF-AH) activity was significantly reduced by sesame lignans. The prolongation of LDL oxidation lag time was abolished by the addition of a PAF-AH inhibitor. The expression level of pro-inflammatory cytokines and macrophage infiltration observed in the liver following the feeding of the fat/cholesterol-enriched diet were also significantly reduced by sesame lignans.
CONCLUSIONS: These results indicate that sesame lignans reduce LDL oxidative susceptibility by downregulating plasma PAF-AH activity via the reduction of inflammation in the liver induced by fat/cholesterol-enriched diets.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
Y. Nakamura, H. Okumura, Y. Ono, Y. Kitagawa, T. Rogi, H. Shibata
Sesame lignans reduce LDL oxidative susceptibility by downregulating the platelet-activating factor acetylhydrolase
Eur Rev Med Pharmacol Sci
Year: 2020
Vol. 24 - N. 4
Pages: 2151-2161
DOI: 10.26355/eurrev_202002_20395